BARD1 Life Sciences (ASX:BD1), a biotechnology company developing non-invasive cancer diagnostics, has announced the Israeli Patent Office issued Israeli Patent number 224766 titled 'BARD1 isoforms in lung and colorectal cancer and use thereof'.
"This patent family protects the sequence of various BARD1 isoforms specific to lung and colorectal cancer, methods for detecting the presence of the specific BARD1 isoforms, and methods for treating and/or preventing lung cancer and colorectal cancer," said the company.
The patent was filed in the name of Université De Genève (UNIGE) and Hôpitaux Universitaires de Genève (HUG) on 17 August 2011 and expires on 17 August 2031.
According to CEO, Dr Leearne Hinch, “This core patent family now has 6 granted patents in the US, Japan and Japan divisional, Israel, China and Australia, with other jurisdictions pending.
"The BARD1 LSL patent portfolio includes 5 patent families covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers.”
The BARD1-Lung test is in development for the early detection of lung cancer. Lung cancer is the fifth most common cancer and the leading cause of cancer death in Australia.
The Australian Institute of Health and Welfare estimates there will be 12,741 new cases of lung cancer diagnosed (9.2 percent of all new cancers diagnosed) and 9,198 deaths from lung cancer (18.9 percent of all cancer deaths) in Australia in 2018.
Lung cancer is often diagnosed at a later stage after it has spread to other parts of the body, resulting in just a 15.8 percent chance of survival after five-years in Australia. Early detection of lung cancer has the potential to save lives by enabling earlier treatment. There is currently no approved blood test available for screening of lung cancer in people without symptoms.